期刊文献+

CpG ODN加强树突状细胞疫苗抗Lewis肺癌的研究 被引量:8

Studies on the enhancement of DC vaccine to mouse Lewis lung cancer by CpG oligonucleotides
原文传递
导出
摘要 目的 探讨CpGODN对树突状细胞 (DC)疫苗抗肿瘤作用的影响。方法 应用ODN182 6作为DC的成熟刺激信号 ,体外控制DC充分成熟 ,以混合或融合的方式将肿瘤抗原负载于DC制备DC疫苗。以特异性杀伤细胞活性和淋巴细胞增殖反应测定疫苗的体外免疫活性 ,并将疫苗经小鼠腹腔注射 ,观察治疗和预防实验肿瘤的生长情况。结果 经ODN 182 6刺激后的DC细胞形态呈成熟状态 ,流式细胞仪分析检测刺激前后DC细胞表面分子CD4 0的表达分别为 11和 2 4 (MFI) ,CD86的表达分别为 33和 75 (MFI) ,刺激后的DC培养上清中IL 12的分泌水平为刺激前的 10倍。刺激后DC融合疫苗组CTL活性、T淋巴细胞增殖活性及体内Lewis肺癌移植瘤的抑瘤率均明显高于未刺激的DC融合组 (P <0 .0 5 )。结论 CpGODN能通过诱导DC成熟 ,增强DC疫苗的抗肿瘤作用 ,有效诱导机体产生特异的抗肿瘤反应。未成熟的DC可通过与肿瘤细胞混合的方式 ,获得较好的抗原捕获效果 ,产生一定的抗肿瘤效应 ,而对于刺激成熟的DC则需通过融合手段负载抗原 ,达到有效的抗肿瘤活性。 Objective To investigate whether CpG ODN can affect the antitumor responses of DC tumor cell vaccine against Lewis lung cancer. Methods CpG oligonucleotides 1826 (ODN 1826) were used to promote maturation of DCs in vitro. By fusing DCs with Lewis lung carcinoma L3 8 cells, DC based tumor cell vaccines were developed. To determine the immune responses to the vaccines, T cell proliferation and cytotoxicity were done in vitro. Theraputic and prophylactic immunization with DC vaccines were performed in C57BL/6 mice bearing Lewis lung carcinoma. Results Bone marrow cells cultured in the presence of GM CSF and IL 4 plus additional ODN 1862 appeared typical morphology of DCs. FACS analyses showed that the mean fluorescence index (MFI) of CD40 expression of DCs stimulated with and without CpG ODN was 24 and 11, respectively, and that of CD86 expression was 75 and 33, respectively. IL 12 secreted by DCs cultured with ODN 1826 was 10 fold as high as that without ODN 1826. Significant T cell proliferation and T cell mediated cytotoxicity against L3 8 was induced in vitro. Marked inhibition of tumor growth in L3 8 bearing mice was observed upon prophylactic and therapeutic immunizations with the vaccine. Conclusion CpG ODN can enhance the antitumor responses of DC vaccine by promoting DC maturation. [
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2005年第1期1-5,共5页 Chinese Journal of Oncology
基金 国家自然科学基金资助项目 (3 980 0 14 7 3 0 2 70 5 88)
关键词 DC疫苗 ODN 刺激 LEWIS肺癌 树突状细胞疫苗 体外 抗肿瘤作用 融合 结论 方式 DC vaccine CpG ODN Cell fusion Neoplasms immunotherapy
  • 相关文献

参考文献9

  • 1黄波,冯作化,张桂梅,李东,王洪涛.Hsp70-H22肿瘤抗原肽复合物激活树突状细胞诱导抗肿瘤免疫的研究[J].中华肿瘤杂志,2002,24(5):421-425. 被引量:12
  • 2Labeur M, Roter B, Pets B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol, 1999, 162: 168-175.
  • 3Krieg AM. Immune effects and mechanisms of action of CpG motifs.Vaccine, 2000, 19: 618-622.
  • 4Biragyn A, Kwak LW. Designer cancer vaccines are still in fasion. NatMed, 2000, 6: 966-968.
  • 5Bromaer C, Serderer J, Sddamp A, et al. Enhanced dendritic maturation by TNF-α or cytidine-phosphate-gutmosine DNA drives T cell activation in vitro and therapeutic anti-tumor inuntme responds in rico. J Immunol, 2000, 165: 6278-6286.
  • 6Mellman I, Steitunan R. Dendritic cells: specialized and regulated antigen processing machine. J Cell, 2001, 106: 255-258.
  • 7Chiodoni C, Paglia P, Stoppacciaro A, et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor( GM-CSF)and CIMO ligand genes take up and present endugenuus tumor-associated antigens, and prim naive mice for a cytotoxic T lymphocyte response. J Exp Med, 1999, 190: 125-133.
  • 8Dallal R, Christakos P, kee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery, 2002, 131: 135-138.
  • 9Edward AD. Manickasingham SP, Sporri R. et al. Microbial recognition via toll-like receptor-dependent and independent pathways determines the cytokine responses of murine dendritic cell subsets to CD40 triggering. J Immunol, 2002, 169: 3652-3660.

二级参考文献14

  • 1Basu S, Binder RJ, Ramalingam T, et al. CD91 is a common receptor for heat shock proteins gp96, hsp70, and calreticulin. Immunity, 2001,14:303-313.
  • 2Somersan S, Larsson M, Fonteneau JF, et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol, 2001, 167: 4844-4852.
  • 3Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor -derived dendritic cell vaccine. Cancer Res, 2001, 61:6451-6458.
  • 4Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature, 1998, 392:245-252.
  • 5Imai N, Harashima N, Ito M, et al. Identification of Lck-derived peptides capable of inducing HLA- A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer, 2001, 94:237-242.
  • 6Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer, 2000, 89:2646-2654.
  • 7Srivastava PK, Menoret A, Basu S, et al. Heat shock proteins come of age:primitive functions acquire new roles in an adaptive world. Immunity, 1998, 8:657-665.
  • 8Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med, 2000, 191:1957-1964.
  • 9Shimizu K, Thomas EK, Giedlin M, et al. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res, 2001, 61:2618-2624.
  • 10Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 2000, 96:3102-3108.

共引文献11

同被引文献54

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部